acp-104
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00628420)
Timeline
Indications
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M1ACTIVATOR
CHRM1 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- acp-104
- acp-104
- acp-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00490516 | Phase 2 | Jun 1, 2007 | Acadia Pharmaceuticals |
| NCT00628420 | Phase 1 | Jan 1, 2005 | Acadia Pharmaceuticals, Stanley Medical Research Institute, The University of Texas, Dallas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals | For profit | 2 | 1 | 2 | 2005 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2005 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2005 |
3 organizations
Page 1 / 1